Fig. 4

FSA exerted protective effect against the oxaliplatin-induced neurotoxicity. (a&b) The PC12 cells were differentiated in the DM for 96 h, and then treated with the various concentrations of FSA (0–80 μΜ) (a) or a combination of oxaliplatin (LOHP) and the indicated concentrations of FSA or EFSF (b). After treatment for 48 h, cell viability was assessed. (c&d) The neural PC12 cells were treated with the EFSF (100 μg/ml) or FSA (40 μΜ) in the presence of LOHP in the DM. The percentages of neural PC12 cells extending neurites (black bar) and their total neurite lengths (grey bar) were calculated using an image software. The data from at least triplicate experiments are presented as the mean ± SD. Images were photographed under an inverted microscope (× 200 magnification). *** p < 0.001 vs. vehicle control, ^## p < 0.01, ^### p < 0.001 vs. LOHP alone